Rafferty Asset Management
RARE icon

Rafferty Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Rafferty Asset Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.47M Buy
165,431
+8,370
+5% +$188K 0.01% 491
2025
Q4 		$3.61M Buy
157,061
+577
+0.4% +$19K 0.01% 521
2025
Q3 		$4.71M Buy
156,484
+75,388
+93% +$2.26M 0.02% 439
2025
Q2 		$2.95M Sell
81,096
-7,716
-9% -$278K 0.01% 505
2025
Q1 		$3.22M Sell
88,812
-12,481
-12% -$519K 0.01% 464
2024
Q4 		$4.26M Buy
101,293
+2,892
+3% +$143K 0.02% 446
2024
Q3 		$5.47M Sell
98,401
-27,758
-22% -$1.41M 0.02% 403
2024
Q2 		$5.19M Sell
126,159
-55,325
-30% -$2.36M 0.02% 407
2024
Q1 		$8.47M Sell
181,484
-40,426
-18% -$1.91M 0.03% 333
2023
Q4 		$10.6M Buy
221,910
+38,859
+21% +$1.51M 0.04% 260
2023
Q3 		$6.53M Buy
183,051
+21,376
+13% +$847K 0.04% 334
2023
Q2 		$7.46M Sell
161,675
-13,900
-8% -$645K 0.04% 311
2023
Q1 		$7.04M Sell
175,575
-22,725
-11% -$975K 0.05% 292
2022
Q4 		$9.19M Buy
198,300
+57,610
+41% +$2.27M 0.08% 199
2022
Q3 		$5.83M Buy
140,690
+64,107
+84% +$3.29M 0.06% 302
2022
Q2 		$4.57M Sell
76,583
-5,154
-6% -$317K 0.04% 292
2022
Q1 		$5.94M Buy
81,737
+14,046
+21% +$977K 0.04% 336
2021
Q4 		$5.69M Buy
67,691
+37,052
+121% +$3.01M 0.03% 330
2021
Q3 		$2.76M Buy
30,639
+4,993
+19% +$451K 0.02% 527
2021
Q2 		$2.44M Sell
25,646
-599
-2% -$62.4K 0.02% 618
2021
Q1 		$2.99M Buy
26,245
+19,812
+308% +$2.7M 0.02% 500
2020
Q4 		$891K Sell
6,433
-20,440
-76% -$2.42M 0.01% 533
2020
Q3 		$2.21M Buy
26,873
+12,840
+91% +$1.06M 0.03% 382
2020
Q2 		$1.1M Buy
14,033
+7,335
+110% +$485K 0.02% 515
2020
Q1 		$298K Sell
6,698
-50,227
-88% -$2.61M 0.01% 439
2019
Q4 		$2.43M Sell
56,925
-41,882
-42% -$1.73M 0.04% 306
2019
Q3 		$4.23M Buy
98,807
+12,306
+14% +$669K 0.07% 174
2019
Q2 		$5.49M Buy
86,501
+21,478
+33% +$1.37M 0.1% 141
2019
Q1 		$4.51M Buy
+65,023
New +$3.72M 0.07% 155

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Rafferty Asset Management's RARE Position: Q1 2026 in Review

Rafferty Asset Management increased its Ultragenyx Pharmaceutical (RARE) stake by 5.3% in Q1 2026, buying an estimated $188K and bringing the position to 165,431 shares worth $3.47M. The position accounts for 0.01% of the portfolio, ranked #491.

Rafferty Asset Management first reported a position in RARE in Q1 2019 and has held it in 29 quarters since. The position peaked at $10.6M in Q4 2023. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Rafferty Asset Management held 165,431 shares of Ultragenyx Pharmaceutical worth $3.47M as of Q1 2026.
  • Rafferty Asset Management bought 8,370 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $188K.
  • Ultragenyx Pharmaceutical made up 0.01% of Rafferty Asset Management's portfolio in Q1 2026, its #491 holding.
  • Rafferty Asset Management first reported a position in Ultragenyx Pharmaceutical in Q1 2019 and has held it in 29 quarters since.
  • Rafferty Asset Management's Ultragenyx Pharmaceutical position peaked at $10.6M in Q4 2023.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.